Metabolic Peptide Guide
GLP-1 Peptides:
Complete Beginner's Guide
What GLP-1 receptor agonists are, how semaglutide, tirzepatide, and retatrutide compare, realistic results timelines, and which compound to start with based on your goals.
01
How GLP-1 Works
GLP-1 (glucagon-like peptide-1) is a gut hormone secreted by intestinal L-cells within minutes of eating. Its job is to signal satiety — to tell the brain that food has arrived and appetite should decrease. In lean, metabolically healthy individuals, this system works well. In obesity and metabolic dysfunction, GLP-1 secretion is blunted and the satiety response is impaired.
GLP-1 receptor agonist peptides bypass this impairment entirely. By delivering a continuous, pharmacological GLP-1 signal — far stronger and longer-lasting than what food intake alone generates — they restore and dramatically amplify the satiety response. The result is a fundamental reduction in caloric drive that operates at the hormonal and neurological level, not the willpower level.
This is why GLP-1 therapy produces weight loss outcomes that no behavioral intervention has ever matched: it addresses the biological drivers of overeating, not just the behavioral ones.
Appetite Suppression via Hypothalamus
GLP-1 receptors are densely expressed in the arcuate nucleus of the hypothalamus — the brain's primary appetite-regulation hub. GLP-1 agonism activates POMC neurons (which generate satiety signals) and inhibits AgRP/NPY neurons (which drive hunger). The result is a dramatic reduction in caloric drive that is pharmacological, not willpower-dependent. Users typically describe feeling full on 30–50% fewer calories without conscious restriction.
Gastric Emptying Delay
GLP-1 slows the rate at which the stomach empties into the small intestine. This produces prolonged feelings of fullness after meals, blunts post-meal glucose spikes, and reduces the frequency and urgency of hunger signals. The gastric emptying effect is most pronounced at lower doses — at higher doses, central appetite suppression dominates. Together, these two mechanisms create a powerful and complementary reduction in caloric intake.
Insulin Sensitization & Glucose Control
GLP-1 stimulates insulin secretion from pancreatic beta cells in a strictly glucose-dependent manner — insulin is released only when blood glucose is elevated, preventing hypoglycemia at baseline. It simultaneously suppresses glucagon from alpha cells, reducing hepatic glucose output. The net effect is dramatically improved glucose tolerance and insulin sensitivity — which has metabolic benefits beyond weight loss, including reduced cardiovascular risk and improved lipid profiles.
Reward Pathway Modulation
GLP-1 receptors are present throughout the mesolimbic dopamine system — the brain's reward circuitry. GLP-1 agonism reduces the motivational salience of food cues, essentially diminishing food cravings and compulsive eating behavior at a neurochemical level. This is a key reason why GLP-1 therapy addresses emotional and hedonic eating, not just physiological hunger — and why compliance rates are dramatically higher than with diet-only or stimulant-based approaches.
02
Three Generations of GLP-1 Therapy
The GLP-1 class has evolved rapidly. Each generation adds receptor targets beyond GLP-1 alone — producing compounding improvements in efficacy. Understanding the receptor pharmacology explains why newer generations outperform older ones by such a wide margin.
| Compound | Receptors | Trial Weight Loss | Best For |
|---|---|---|---|
Semaglutide 1st Generation | GLP-1R | ~14.9% STEP-1 (68 weeks) | First-time GLP-1 users. Best safety track record, most clinical data, most forgiving titration profile. Ideal starting point. |
Tirzepatide 2nd Generation | GLP-1R + GIPR | ~20.9% SURMOUNT-1 (72 weeks) | Intermediate users or those needing greater efficacy. Dual agonism adds ~40% more weight loss vs. semaglutide. Superior metabolic profile. |
Retatrutide 3rd Generation | GLP-1R + GIPR + GCGR | ~24.2% Phase 2 (48 weeks) | Advanced users seeking maximum fat loss or those who have plateaued on tirzepatide. Triple agonism adds thermogenic glucagon effect. |
Semaglutide
Ozempic / Wegovy — 1st Generation
Titration Schedule
0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg (each step 4 weeks)
Tirzepatide
Mounjaro / Zepbound — 2nd Generation
Titration Schedule
2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg (each step 4 weeks)
Retatrutide
Pipeline (LY3437943) — 3rd Generation
Titration Schedule
2mg → 4mg → 8mg → 12mg (each step 4 weeks, max 12mg weekly)
03
Results Timeline
Week 1–2
WHAT HAPPENS
Titration begins at lowest dose. Some nausea and reduced appetite. Most users notice they feel full sooner at meals.
TYPICAL RATE
~0.5–1 lb/week
Gastrointestinal adaptation period. Eat smaller meals and avoid fatty foods to minimize nausea.
Weeks 3–6
WHAT HAPPENS
Appetite suppression increases with dose escalation. Food noise diminishes. First meaningful weight loss becomes visible.
TYPICAL RATE
~1–1.5 lbs/week
The "food noise" reduction — the constant background thoughts about eating — is often the most striking early effect.
Weeks 7–10
WHAT HAPPENS
Approaching therapeutic dose range. Energy levels stabilize as the body adapts. Fat loss accelerating as caloric deficit compounds.
TYPICAL RATE
~1.5–2 lbs/week
Most users reach 5–8% total body weight reduction by week 10. Metabolic benefits (glucose, blood pressure) measurable at labs.
Week 11–16+
WHAT HAPPENS
Full therapeutic dose established. Maximum appetite suppression. Body composition shifting — fat loss preserved, muscle mass maintained with adequate protein intake.
TYPICAL RATE
~1–2 lbs/week
Protein intake of 1g/lb of target bodyweight is critical at this stage to preserve lean mass during aggressive caloric restriction.
04
Who Should Use Which
Beginners — Start with Semaglutide
- →No prior GLP-1 experience
- →Want the best-validated safety record (10+ years of data)
- →Prefer the longest track record and most clinical literature
- →14.9% average weight loss is substantial for most users
- →Most forgiving titration — can pause/slow at any dose
Intermediate — Upgrade to Tirzepatide
- →Completed a semaglutide cycle or want greater efficacy from the start
- →Body weight loss goal exceeds what semaglutide typically achieves
- →Managing type 2 diabetes (tirzepatide has superior HbA1c reduction)
- →20.9% average weight loss — substantially greater than semaglutide
- →Dual receptor mechanism improves lipid profile more than pure GLP-1
Advanced / Maximum Fat Loss — Retatrutide
- →Seeking maximum possible fat loss (24.2% in Phase 2 — highest recorded)
- →Plateaued on tirzepatide and need additional thermogenic effect
- →Glucagon receptor agonism increases resting energy expenditure
- →Particularly effective for visceral adiposity and metabolic syndrome
- →Triple agonism produces the most dramatic body recomposition results
Get GLP-1 Peptides
06
Dosing Protocols
All three compounds are dosed once weekly via subcutaneous injection. The principle is the same across all three: start at the lowest possible dose and titrate up every 4 weeks. Rushing titration is the primary driver of GI side effects. There is no clinical benefit to reaching maximum dose faster — therapeutic weight loss occurs at every dose level.
Injection Technique
Subcutaneous injection into abdominal fat (2 inches from navel), outer thigh, or upper arm. Pinch the skin, insert at 45-90°, inject slowly, remove. Rotate sites weekly.
Needle Specifications
Insulin syringe: 29–31 gauge, 4–8mm (5/16 inch) needle length. Pull up the weekly dose and inject. No special preparation required beyond standard sterile technique.
Reconstitution
Research peptide vials are lyophilized (freeze-dried). Reconstitute with bacteriostatic water. Standard dilution: 2ml bac water per 5mg vial for easy volume measurement. See the full reconstitution guide for step-by-step instructions.
Storage
Unreconstituted vials: refrigerate or freeze for extended storage. Reconstituted solution: refrigerate, use within 28 days. Never freeze reconstituted peptides. Avoid light exposure during storage.
Managing GI Side Effects During Titration
Nausea is the most common early side effect and is entirely dose-dependent. Strategies that reliably reduce it: eat smaller, lower-fat meals; avoid eating to fullness; inject at night (sleep through peak plasma levels); keep ginger tea on hand for the first week at each new dose level. Most users find nausea minimal or absent after 1–2 weeks at any given dose.
If nausea is significant at a new dose, hold that dose for an additional 4 weeks before attempting to escalate. There is no penalty for a longer titration — many users reach their goal weight at intermediate doses and never need maximum dose.
07
Frequently Asked Questions
What is a GLP-1 peptide?
GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells after eating. GLP-1 receptor agonists mimic and amplify this signal, producing powerful appetite suppression, slowed gastric emptying, improved insulin sensitivity, and substantial body weight reduction. They are the most clinically validated weight-loss compounds available.
Is GLP-1 therapy safe?
GLP-1 receptor agonists are among the most extensively studied compounds in metabolic medicine. Semaglutide has been evaluated in 10,000+ patients across multi-year trials. Common side effects — nausea, constipation — are GI-related and resolve with slow titration. Long-term cardiovascular data (SELECT trial) shows semaglutide reduces major adverse cardiovascular events by 20%, indicating cardiovascular benefit beyond weight loss.
How fast do you lose weight on GLP-1 peptides?
Typically 1–2 lbs per week once at therapeutic dose. Clinical trial averages: semaglutide 14.9% body weight over 68 weeks, tirzepatide 20.9% over 72 weeks, retatrutide 24.2% over 48 weeks. These are averages — metabolic responders achieve significantly more, and results are amplified with protein-adequate nutrition and resistance training.
What is the difference between semaglutide, tirzepatide, and retatrutide?
Generation defines the difference. Semaglutide activates GLP-1 receptors only. Tirzepatide adds GIP receptor co-agonism, which amplifies GLP-1 signaling and adds ~40% greater weight loss. Retatrutide adds glucagon receptor agonism on top of both — the glucagon component increases thermogenesis (resting energy expenditure), producing the highest weight loss of any compound tested to date.
Do you need to inject GLP-1 peptides?
Research formulations of semaglutide, tirzepatide, and retatrutide are all administered via once-weekly subcutaneous injection. The injection uses an insulin syringe with a 4–8mm needle into subcutaneous fat — a straightforward process most users adapt to quickly. The once-weekly dosing interval makes the injection burden minimal.
Related Guides
Full Three-Way Comparison →
Side-by-side analysis of all three compounds with trial data, receptor mechanisms, and which to choose
Tirzepatide Complete Guide →
Dual GIP+GLP-1 mechanism, SURMOUNT trial data, full 2.5–15mg titration protocol
Semaglutide Complete Guide →
The definitive semaglutide guide — STEP trial results, dosing, and side effect management
Retatrutide Complete Guide →
Triple agonist mechanism, Phase 2 results, and the maximum fat loss protocol
Reconstitution Guide →
Step-by-step guide to mixing, storing, and dosing research peptides correctly
All Peptide Guides →
Browse every in-depth protocol and research article on PeptidesMuscle
